Chua CC et al. An Australasian Leukemia Lymphoma Group (ALLG) phase 2 study to investigate novel triplets to extend remission with venetoclax in elderly (INTERVENE) acute myeloid leukemia. ASH 2021;Abstract 368.
DiNardo CD et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol 2021;22(11):1597-608. Abstract
Döhner H et al. Towards precision medicine for AML. Nat Rev Clin Oncol 2021;18(9):577-90. Abstract
Larson RA et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: The Alliance CALGB 10603/RATIFY trial. Leukemia 2021;35(9):2539-51. Abstract
Loo S, Wei AH. Post-transplant maintenance therapy for MDS and AML: A bridge too far or the beginning of a new era? Leuk Lymphoma 2021;62(13):3073-7. Abstract
Pullarkat V et al. Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms. ASCO 2021;Abstract 7011.
Ravandi F et al. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: Experience from the phase 3 randomized QUAZAR AML-001 trial. J Hematol Oncol 2021;14(1):133. Abstract
Roberts AW et al. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood 2021;138(13):1120-36. Abstract
Roboz GJ et al. Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: Results from the phase 3, placebo-controlled QUAZAR AML-001 trial. Haematologica 2021;106(12):3240-4. Abstract
Tiong IS et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv 2021;5(23):5107-11. Abstract
Wei AH et al. Long-term overall survival (OS) with oral azacitidine (oral-aza) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC): Updated results from the phase 3 QUAZAR AML-001 trial. ASH 2021;Abstract 871.